Creo - Unlocking the potential of rare cannabinoids
Private company Creo is a potential disrupter in the cannabinoids space, leveraging its proprietary bacterial fermentation technology to manufacture hitherto uneconomical rare cannabinoids at commercial scale. Initial focus is on cannabigerol (CBG), a non-psychoactive cannabinoid with potential application across the health, wellness and beauty industries. With its first commercial 28,000L manufacturing run achieved in August 2021 and collaboration agreements with Fifth & Root and Joiya announced, we expect Creo to commence revenue generation in 2021. Continued manufacturing campaigns and the development of partnerships should continue building momentum.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.